of 1 /1
Vaccine 31S (2013) G81 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Disclosure of financial support This project has been coordinated by the Cancer Epidemiology Research Program (CERP) at the Catalan Institute of Oncology – Institut Català d’Oncologia (ICO) in Barcelona, Spain. We acknowledge with gratitude the support received from the following government and corporate organizations: Partial support for this project was received from The Bill and Melinda Gates Foundation (grant reference V20-181-15) for the development of the WHO/ICO Information Centre on HPV and Cancer; Spanish public grants from Instituto de Salud Carlos III (Span- ish Government) (grants RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056 and CIBERESP) and from the Agència de Gestió d’Ajuts Universitaris i de Recerca – Gen- eralitat de Catalunya (Catalan Government) (grants AGAUR 2005SGR00695 and AGAUR 2009SGR126), and from B-DEBATE International Center for Scientific Debate Barcelona/BIOCAT. The ICO Monograph Series on HPV and Disease Prevention has received additional support from: HPV vaccine producers/distributors HPV diagnostics GlaxoSmithKline Merck & Co. Sanofi Pasteur MSD Abbott Becton Dickinson Genomica Hologic/Gen-Probe/Grifols Roche Molecular Diagnostics/MTM No financial sponsor, public or private, intervened in the iden- tification of topics, selection of editors or in the preparation or approval of the Monograph series. Representatives from public and private financial sponsors were invited as observers to the peer- review meeting held in Sitges, Barcelona, Spain in March 21–24, 2012. The authors are solely responsible for the contents of each indi- vidual chapter. The statements and conclusions described might not necessarily represent the views or the position of the orga- nizations or institutions in which they serve. Each author was requested to disclose any potential conflict of interests and a sum- mary of the individual disclosure is presented at the end of each article. F. Xavier Bosch on behalf of the Editors Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology – Institut Català d’Oncologia (ICO), Avda. Gran Via 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain Tel.: +34 932607812; fax: +34 932607787. E-mail address: [email protected] 0264-410X/$ – see front matter http://dx.doi.org/10.1016/j.vaccine.2013.10.005

Disclosure of financial support

Embed Size (px)

Text of Disclosure of financial support

Page 1: Disclosure of financial support

D

RI

f

r

0h

Vaccine 31S (2013) G81

Contents lists available at ScienceDirect

Vaccine

journa l homepage: www.e lsev ier .com/ locate /vacc ine

isclosure of financial support

Tel.: +34 932607812; fax: +34 932607787.E-mail address: [email protected]

This project has been coordinated by the Cancer Epidemiologyesearch Program (CERP) at the Catalan Institute of Oncology –

nstitut Català d’Oncologia (ICO) in Barcelona, Spain.We acknowledge with gratitude the support received from the

ollowing government and corporate organizations:

Partial support for this project was received from The Bill andMelinda Gates Foundation (grant reference V20-181-15) for thedevelopment of the WHO/ICO Information Centre on HPV andCancer;Spanish public grants from Instituto de Salud Carlos III (Span-ish Government) (grants RCESP C03/09, RTICESP C03/10, RTICRD06/0020/0095, RD12/0036/0056 and CIBERESP) and from theAgència de Gestió d’Ajuts Universitaris i de Recerca – Gen-eralitat de Catalunya (Catalan Government) (grants AGAUR2005SGR00695 and AGAUR 2009SGR126), and from B-DEBATEInternational Center for Scientific Debate Barcelona/BIOCAT.

The ICO Monograph Series on HPV and Disease Prevention haseceived additional support from:

HPV vaccineproducers/distributors

HPV diagnostics

GlaxoSmithKline Abbott

Merck & Co.Sanofi Pasteur MSD

Becton DickinsonGenomicaHologic/Gen-Probe/GrifolsRoche Molecular Diagnostics/MTM

264-410X/$ – see front matterttp://dx.doi.org/10.1016/j.vaccine.2013.10.005

No financial sponsor, public or private, intervened in the iden-tification of topics, selection of editors or in the preparation orapproval of the Monograph series. Representatives from public andprivate financial sponsors were invited as observers to the peer-review meeting held in Sitges, Barcelona, Spain in March 21–24,2012.

The authors are solely responsible for the contents of each indi-vidual chapter. The statements and conclusions described mightnot necessarily represent the views or the position of the orga-nizations or institutions in which they serve. Each author wasrequested to disclose any potential conflict of interests and a sum-mary of the individual disclosure is presented at the end of eacharticle.

F. Xavier Boschon behalf of the Editors

Cancer Epidemiology Research Program (CERP),Catalan Institute of Oncology – Institut Català d’Oncologia (ICO),

Avda. Gran Via 199-203, 08908 L’Hospitalet de Llobregat,Barcelona, Spain